Press release: Novo Nordisk files for FDA approval of a higher dose of Wegovy injection 7.2 mg
Contact your GP, specialist, or clinical trial team promptly if you experience: A spreading rash , hives (urticaria), or widespread skin redness that develops after starting treatment Swelling of the face, lips, tongue, or throat , which may indicate angioedema a potentially serious allergic reaction requiring urgent assessment Difficulty breathing or swallowing alongside skin changes call 999 immediately , as this could indicate anaphylaxis Signs of infection at an injection site , including increasing warmth, pus, significant swelling, or fever Persistent or worsening skin symptoms that do not improve with basic self-care measures after one to two weeks Unexplained bruising or bleeding beyond what would be expected from a subcutaneous injection If you are unsure whether your symptoms require urgent attention, NHS 111 can provide guidance
Cannot be used for pediatric patients
If you have any questions or concerns, please talk to a medical professional
All our peptides are supplied as lyophilized (freeze-dried) powders, which are very stable for shipping
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved its use, and it is increasingly prescribed for glycaemic control